RankAlpha logo
Back to Rankings

TARA

Protara TherapeuticsD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-22
View Chart
Current thesis
Primary-source updates show genuine momentum: the lead NMIBC program posted a 68.0% six-month CR rate in the first 25 BCG-unresponsive patients, management reiterated 2H 2026 registrational milestones, and the LM program has Breakthrough/Fast Track support plus an expected 1H 2026 regulatory update [#8-K-2026-03-30][#PR-2026-03-10][#PR-2026-01-05].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -1.0.
What can break
Clinical and regulatory outcomes remain binary across both TARA-002 and IV Choline Chloride.
Momentum
11
Value
41
Sentiment
77
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.00 · Bull $9.00 · Bear $2.75
Data freshness
Prices
As of 2026-07-22
Fundamentals
As of 2026-07-22 • Vendor: Data Vendor v1
Scores
As of 2026-07-22 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-22
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $26.57
Why
Momentum11 · Δ7d +14.0
Value41 · Δ7d -0.0
Sentiment77 · Δ7d -1.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
11
26% active weight
Current posture
7d trendImproving
Δ7d
+14.0
Δ21d
+13.5
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.1
Sentiment
77
34% active weight
Current posture
7d trendSoftening
Δ7d
-1.0
Δ21d
-10.3
Why this grade

Composite grade D. Momentum 11.3 / Value 41.1 / Sentiment 77.0

Fundamentals (TTM)
As of 2026-07-22
Market Cap
$229.31M
Beta
1.37
Shares Out
56.2M
P/E (TTM) · Derived
-3.0
P/S (TTM)
-
P/FCF (TTM) · Derived
-3.08
Rev YoY
-100.0%
EPS YoY
+5.6%
Gross Margin
-
Op Margin
-
Net Debt
-$152.2M
Current Ratio
15.69
As of 2026-07-22 • Updated nightlySource: Internal modelMethodology